Drugs / AZD5153
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03527147 | Jun 2018 → Mar 2021 | diffuse large B-cell lymphoma | Acerta Pharma BV | Completed | No outcome recorded |
| Phase 1 | NCT03205176 | Jun 2017 → Mar 2021 | breast cancer, lymphoma, malignant pancreatic neoplasm, ovarian cancer +1 | AstraZeneca | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03013998 | Nov 2016 → Dec 2028 expected | acute myeloid leukemia | Beat AML, LLC | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD5153 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03205176 ↗ |
| Action | Inhibit | “BRD4 inhibitor” NCT03527147 ↗ |
| Modality | Small molecule | — CHEMBL4078100 ↗ |
| Route | Oral | “20 mg, oral, once daily” NCT03013998 ↗ |
| Target | BRD4 | “BRD4 inhibitor” NCT03527147 ↗ |